MENLO PARK, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today announces the appointment of Alison "Ali" Bauerlein as its Chief Financial Officer and Treasurer, effective April 3, 2023. "I am incredibly excited to have Ali join Sight Sciences as we scale our business and drive towards profitable growth. Ali is an exceptionally talented professional with a proven track record of leading a rapidly growing medtech organization through multiple phases of growth. Her experience and talent will prov

 Gelesis has demonstrated strong demand for Plenity, helping over 200,000 people on their weight loss journeys since launch Company has filed with FDA to make Plenity available to Over the Counter (OTC), which should significantly broaden consumer access and reduce the cost to reach new members Gelesis Holdings, Inc. (NYSE:GLS) ("Gelesis" or the "Company"), the maker of Plenity for weight management, today reported financial results for the year ended December 31, 2022. Plenity is a novel orally administered, FDA-cleared weight management therapy that helps people feel satisfied with smaller portions, so they can eat less and lose weight, while still enjoying the foods they love. Plenity

Gelesis (NYSE:GLS), the maker of Plenity for weight management, today announced that the Company will participate in the 25th Annual ICR Conference in Orlando, Florida on Monday, January 9, 2023. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230105005182/en/Gelesis is the maker of Plenity, an FDA-cleared weight management product. (Graphic: Business Wire) Gelesis will host a presentation at 1:30 p.m. ET. The live webcast can be accessed on the "Events & Presentations" section of the Gelesis Investor Relations website at https://ir.gelesis.com/. The webcast will also be archived and available for replay. About Gelesis Gelesis H

Rapid advancement of PureTech's Wholly Owned Pipeline, with three clinical trials now underway and five completed this year that demonstrated compelling safety and tolerability data for LYT-100 (deupirfenidone) and proof of principle, oral bioavailability and tolerability for LYT-300 (oral allopregnanolone). Robust dose escalation and safety data also announced from completed monotherapy portion of Phase 1 program for LYT-200 (anti-galectin-9 mAb) Catalyst-rich 2023 anticipated, with results from late-stage trial of LYT-100 in idiopathic pulmonary fibrosis and Phase 1b trial of LYT-200 in leukemia. Initiation of clinical trials planned with LYT-300 and LYT-310 (oral cannabidiol) targeting

The Company Intends to Cure Deficiency and Return to Compliance with NYSE Listing Standard Gelesis Holdings Inc. (NYSE:GLS) ("Gelesis" or the "Company") today noted that on November 16, 2022, the Company received a notification letter (the "Notice") from the New York Stock Exchange (the "NYSE") advising that it was not in compliance with the continued listing standard set forth in Section 802.01B of the NYSE Listed Company Manual because its total market capitalization was less than $50 million over a 30 trading-day period and its stockholders' equity was less than $50 million over a separate 30 trading-day period. The Company's common stock will continue to be listed and traded on the NYS

Plenity quarterly product revenue increased 114% year-over-year to $6.4 million, with 23,500 new members and 92,000 units sold in Q3 Quarterly gross profit increased by $2.6 million year-over-year, with gross margin improving from 8% to 44% Company is preparing to submit Plenity for Over the Counter (OTC) status, which would make it available without the need for a prescription and further reduce cost of customer acquisition Gelesis Holdings, Inc. (NYSE:GLS) ("Gelesis" or the "Company"), the maker of Plenity for weight management, today reported financial results for the third quarter of 2022. Plenity is a novel orally administered, FDA-cleared weight management therapy that helps people

Gelesis Holdings, Inc. (NYSE:GLS) ("Gelesis" or the "Company"), the maker of Plenity® for weight management, today announced that the Company will report financial results for the third quarter ended September 30, 2022, on November 14, 2022 prior to the market open. Gelesis management will host a live conference call and webcast at 8:30 a.m. ET on the same day to discuss the results. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221107005166/en/Gelesis is a consumer-centered biotherapeutics company and the maker of Plenity for weight management. (Photo: Business Wire) The live call can be accessed via webcast on the "Events & Pr

The Company Intends to Cure Deficiency and Return to Compliance with NYSE Listing Standard Gelesis Holdings Inc. (NYSE:GLS) ("Gelesis" or the "Company") today noted that the Company received a notification letter from the New York Stock Exchange (the "NYSE") advising that because the average closing price of the Company's common stock was less than $1.00 over a consecutive 30 trading-day period, it is not in compliance with Section 802.01C of the NYSE Listed Company Manual. The Company's common stock will continue to be listed and traded on the NYSE, subject to the Company's compliance with other NYSE continued listing standards. The Company can regain compliance at any time within the si

Akkermansia muciniphila has been associated with thickened mucosal lining of the gut, improved gut barrier function, and lean body mass Gelesis Holdings Inc. (NYSE:GLS) ("Gelesis" or the "Company") the maker of Plenity for weight management, today released new data at Obesity Week in San Diego. The study investigated how an oral superabsorbent hydrogel (Gel-B or GS200) increases Akkermansia muciniphila in comparison to two prebiotics, inulin, and psyllium A. muciniphila is a bacteria associated with thickened mucosal lining of the gut, that encourages improved gut barrier function, and lean body mass. This press release features multimedia. View the full release here: https://www.businessw

Waist to Height Ratio, known to be correlated with insulin resistance & metabolic syndrome, was a predictor of weight loss response in the study based on a post-hoc analysis As previously reported, the LIGHT-UP study met its primary endpoint with 6 out of 10 responding to the treatment, achieving an average of 11% weight loss and 5.6 inches reduction of their waist within only 25 weeks Gelesis Holdings Inc. (NYSE:GLS) ("Gelesis" or the "Company") the maker of Plenity for weight management, today announced Dr. Frank Greenway will give an oral presentation at Obesity Week in San Diego, on Wednesday, November 2 at 4:00pm PDT. This press release features multimedia. View the full release here

MENLO PARK, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today announces the appointment of Alison "Ali" Bauerlein as its Chief Financial Officer and Treasurer, effective April 3, 2023. "I am incredibly excited to have Ali join Sight Sciences as we scale our business and drive towards profitable growth. Ali is an exceptionally talented professional with a proven track record of leading a rapidly growing medtech organization through multiple phases of growth. Her experience and talent will prov

 Gelesis has demonstrated strong demand for Plenity, helping over 200,000 people on their weight loss journeys since launch Company has filed with FDA to make Plenity available to Over the Counter (OTC), which should significantly broaden consumer access and reduce the cost to reach new members Gelesis Holdings, Inc. (NYSE:GLS) ("Gelesis" or the "Company"), the maker of Plenity for weight management, today reported financial results for the year ended December 31, 2022. Plenity is a novel orally administered, FDA-cleared weight management therapy that helps people feel satisfied with smaller portions, so they can eat less and lose weight, while still enjoying the foods they love. Plenity

Plenity quarterly product revenue increased 114% year-over-year to $6.4 million, with 23,500 new members and 92,000 units sold in Q3 Quarterly gross profit increased by $2.6 million year-over-year, with gross margin improving from 8% to 44% Company is preparing to submit Plenity for Over the Counter (OTC) status, which would make it available without the need for a prescription and further reduce cost of customer acquisition Gelesis Holdings, Inc. (NYSE:GLS) ("Gelesis" or the "Company"), the maker of Plenity for weight management, today reported financial results for the third quarter of 2022. Plenity is a novel orally administered, FDA-cleared weight management therapy that helps people

Gelesis Holdings, Inc. (NYSE:GLS) ("Gelesis" or the "Company"), the maker of Plenity® for weight management, today announced that the Company will report financial results for the third quarter ended September 30, 2022, on November 14, 2022 prior to the market open. Gelesis management will host a live conference call and webcast at 8:30 a.m. ET on the same day to discuss the results. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221107005166/en/Gelesis is a consumer-centered biotherapeutics company and the maker of Plenity for weight management. (Photo: Business Wire) The live call can be accessed via webcast on the "Events & Pr

Plenity Q2 product revenue increased 312% year-over-year to $9.0 million Gross profit in Q2 increased by $4.0 million year-over-year, with gross margin improving to 47% from 8% Gelesis (NYSE:GLS), the maker of Plenity for weight management, today reported financial results for the second quarter of 2022. "We are seeing both consumers and clinicians embracing Plenity, with continued growth in both of our distribution channels. We are excited by the fact that consumers are ordering quarterly kits at the start of their treatment journey as well as by our refill rates," said Yishai Zohar, Founder and CEO of Gelesis. "There has been incredible momentum in obesity care and finally, patients ha

Gelesis Holdings, Inc. (NYSE:GLS) ("Gelesis" or the "Company"), the maker of Plenity® for weight management, today announced that the Company will report financial results for the Second Quarter ended June 30, 2022, on August 15, 2022 prior to the market open. Gelesis management will host a live conference call and webcast at 8:30 a.m. ET on the same day to discuss the results. The live call can be accessed via webcast on the "Events & Presentations" section of the Gelesis Investor Relations website at https://ir.gelesis.com/. The webcast will also be archived and available for replay shortly after the call has concluded. Those who are interested in participating in the live call can dial

Plenity product revenue increased 142% year-over-year to $7.5 million in the quarter, driven by the debut of the national media campaign in February 2022 Q1 2022 gross margin increased 277% year-over-year Company reiterates guidance of $58M in projected product revenue for 2022 Gelesis (NYSE:GLS), the maker of Plenity for weight management, today reported financial results for the first quarter of 2022. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220512005826/en/Gelesis' net product revenue was $7.5 million for the first quarter 2022, a 142% increase over the first quarter 2021, driven by the launch of the company's first n

Gelesis (NYSE:GLS), the maker of Plenity® for weight management, today announced that the Company will report financial results for the First Quarter ended March 31, 2022, on May 12, 2022 following the market close. Gelesis management will host a live conference call and webcast at 4:30 p.m. ET on the same day to discuss the results. Conference Call Details Date: Thursday, May 12, 2022 Time: 4:30 p.m. Eastern Time Toll-free dial-in number: (844) 200-6205 International dial-in number: (833) 950-0062 Access code: 037784 The live conference call webcast can be accessed on the Gelesis Investor Relations website at https://ir.gelesis.com/. The webcast will also be archived and available for re

The Company ended the year with 79,100 total members for Plenity®, demonstrating strong demand ahead of first quarter 2022 debut media campaign Gelesis reaffirms guidance for $58 million in product revenue and anticipates 400% growth in 2022 following strong early launch results reported earlier this month, including record-high levels of prescriptions and online traffic Gelesis (NYSE:GLS), the maker of Plenity for weight management, today reported financial results for its fiscal year ended December 31, 2021. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220324005636/en/Gelesis ended the year with 79,100 total members for Ple

Gelesis (NYSE:GLS), the maker of Plenity® for weight management, today announced that the Company will report financial results for fiscal year 2021 on March 24, 2022, following the market close. Gelesis management will host a live conference call and webcast at 4:30 p.m. ET on the same day to discuss the results. The live conference call webcast can be accessed on the Gelesis Investor Relations website at https://ir.gelesis.com/. The webcast will also be archived and available for replay shortly after the call has concluded. About Gelesis Gelesis Holdings Inc. (NYSE:GLS) ("Gelesis") is a consumer-centered biotherapeutics company advancing a novel category of treatments for weight manage

In addition to PureTech's advanced Wholly Owned Pipeline, Founded Entities are an additional source of value and Akili is now set to join the growing list of publicly-traded Founded Entities for PureTech, which also include Karuna Therapeutics (NASDAQ:KRTX), Vor Biopharma (NASDAQ:VOR) and Gelesis (NYSE:GLS) Fully committed PIPE of $162 million led by $100 million from Social Capital with remaining $62 million from new and existing investors including: Suvretta Capital Management's Averill strategy, Apeiron Investment Group, Temasek, co-founder PureTech Health, Polaris Partners, Evidity Health Capital, JAZZ Venture Partners and Omidyar Technology Ventures Transaction values the combined co

SC 13D/A - GELESIS HOLDINGS, INC. (0001805087) (Subject)

SC 13D/A - GELESIS HOLDINGS, INC. (0001805087) (Subject)

SC 13D/A - GELESIS HOLDINGS, INC. (0001805087) (Subject)

SC 13D/A - GELESIS HOLDINGS, INC. (0001805087) (Subject)

SC 13D/A - GELESIS HOLDINGS, INC. (0001805087) (Subject)

SC 13D/A - GELESIS HOLDINGS, INC. (0001805087) (Subject)

SC 13D/A - GELESIS HOLDINGS, INC. (0001805087) (Subject)

SC 13D/A - GELESIS HOLDINGS, INC. (0001805087) (Subject)

SC 13D/A - GELESIS HOLDINGS, INC. (0001805087) (Subject)

SC 13G/A - GELESIS HOLDINGS, INC. (0001805087) (Subject)

4 - GELESIS HOLDINGS, INC. (0001805087) (Issuer)

4 - GELESIS HOLDINGS, INC. (0001805087) (Issuer)

4 - GELESIS HOLDINGS, INC. (0001805087) (Issuer)

4 - GELESIS HOLDINGS, INC. (0001805087) (Issuer)

4 - GELESIS HOLDINGS, INC. (0001805087) (Issuer)

4 - GELESIS HOLDINGS, INC. (0001805087) (Issuer)

4 - GELESIS HOLDINGS, INC. (0001805087) (Issuer)

4 - GELESIS HOLDINGS, INC. (0001805087) (Issuer)

4 - GELESIS HOLDINGS, INC. (0001805087) (Issuer)

4 - GELESIS HOLDINGS, INC. (0001805087) (Issuer)

8-K - GELESIS HOLDINGS, INC. (0001805087) (Filer)

CT ORDER - GELESIS HOLDINGS, INC. (0001805087) (Filer)

8-K - GELESIS HOLDINGS, INC. (0001805087) (Filer)

SC 13E3/A - GELESIS HOLDINGS, INC. (0001805087) (Subject)

PRER14A - GELESIS HOLDINGS, INC. (0001805087) (Filer)

8-K - GELESIS HOLDINGS, INC. (0001805087) (Filer)

SC 13E3/A - GELESIS HOLDINGS, INC. (0001805087) (Subject)

PRER14A - GELESIS HOLDINGS, INC. (0001805087) (Filer)

8-K - GELESIS HOLDINGS, INC. (0001805087) (Filer)

8-K - GELESIS HOLDINGS, INC. (0001805087) (Filer)